Aventis Pharma S.a.

Rhone-poulenc Rorer S.a.

Christophe Marcireau

Marie-Christine Multon

Valerie Polard-Housset

Daniel Scherman

Alain Fournier

Reinhard Fleer

Didier Branellec

Abderrahim Mahfoudi

The present invention relates to a novel protein of the MEKK signal transduction pathway, and the gene encoding it. The invention further relates to diagnostic and therapeutic uses of the protein or the gene, and to methods of screening for agonists or antagonists of the protein, particularly with respect to MEKK activity. In particular, the invention provides a gene encoding MIF1, the MIF1 protein, and antibodies that specifically bind MIF1. MIF1 and the MIF1 gene can be used in screening assays, particularly to identify agonists and antagonists of MIF1 interaction with MEKK, and thus modulators of the MEKK signal pathway. MIF1 gene (or cDNA) can also be delivered to cells, e.g., for in vitro screening or testing, or in vivo or ex vivo for gene therapy.

MEKK1-interacting FHA protein 1 (MIF1)

MEKK1 (serine threonine kinases)-interacting FHA (forkhead associated domain) protein 1 (M1F1)

This invention pertains to polynucleotides comprising GAX domains involved in GAX biological activity. It may pertain, notably, to domains involved in the interaction of GAX with other molecules or domains that are responsible for biological activity. The invention also pertains to chimeric molecules comprising a GAX functional domain. It also pertains to the use of GAX to repress gene expression, as well as the use of compounds that inhibit GAX interaction with certain cellular partners to modulate GAX activity. It also pertains to a method for screening and/or identifying GAX cellular partners.

Polypeptides comprising domains of the GAX protein implicated in the

Yeast with modified permeability

Growing community of inventors

Paris, France

Christophe Marcireau